The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action

2017 ◽  
Vol 400 ◽  
pp. 175-182 ◽  
Author(s):  
Xuan Shi ◽  
Hai-Rong Zhu ◽  
Tao-Tao Liu ◽  
Xi-Zhong Shen ◽  
Ji-Min Zhu
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hippo Pathway ◽  
Non Coding Rnas ◽  
The Hippo Pathway

scholarly journals Hepatic Hippo signaling inhibits development of hepatocellular carcinoma

2020 ◽  
Vol 26 (4) ◽  
pp. 742-750
Author(s):  
Yuchen Liu ◽  
Xiaohui Wang ◽  
Yingzi Yang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Hippo Pathway ◽  
Hepatocyte Proliferation ◽  
Binding Motif ◽  
Hippo Signaling ◽  
Human Liver Cancer ◽  
Kinase Cascade ◽  
The Hippo Pathway

Primary liver cancer is one of the most common cancer worldwide. Hepatocellular carcinoma (HCC) in particular, is the second leading cause of cancer deaths in the world. The Hippo signaling pathway has emerged as a major oncosuppressive pathway that plays critical roles inhibiting hepatocyte proliferation, survival, and HCC formation. A key component of the Hippo pathway is the inhibition of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ) transcription factors by the Hippo kinase cascade. Aberrant activation of YAP or TAZ has been found in several human cancers including HCC. It is also well established that YAP/TAZ activation in hepatocytes causes HCC in mouse models, indicating that YAP/TAZ are potential therapeutic targets for human liver cancer. In this review, we summarize the recent findings regarding the multifarious roles of Hippo/YAP/TAZ in HCC development, and focus on their cell autonomous roles in controlling hepatocyte proliferation, differentiation, survival and metabolism as well as their non-cell autonomous in shaping the tumor microenvironment.

scholarly journals RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma

2013 ◽  
Vol 11 (7) ◽  
pp. 748-758 ◽  
Author(s):  
Ei Yong Ahn ◽  
Ji Su Kim ◽  
Gi Jeong Kim ◽  
Young Nyun Park
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hippo Pathway ◽  
The Hippo Pathway

scholarly journals Homoharringtonine Exerts Anti-tumor Effects in Hepatocellular Carcinoma Through Activation of the Hippo Pathway

2021 ◽  
Vol 12 ◽  
Author(s):  
Haina Wang ◽  
Rui Wang ◽  
Dan Huang ◽  
Sihan Li ◽  
Beibei Gao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hippo Pathway ◽  
Inhibitory Effect ◽  
Invasion And Migration ◽  
Pathway Activation ◽  
Promising Target ◽  
And Migration ◽  
Induced Apoptosis ◽  
The Hippo Pathway

Hepatocellular carcinoma (HCC) is the most prevalent subtype of liver cancer with a mortality rate of approximately 3–6/100,000 and is the third leading cause of cancer-related death worldwide. Although several small-molecule drugs have been developed for the treatment of HCC, the choice of an agent for patients who require systemic chemotherapy at an advanced stage is still limited. The Hippo pathway is an evolutionarily conserved tumor suppressive pathway commonly dysregulated in HCC, which makes it a promising target for anti-HCC therapies. Homoharringtonine (HHT) is an FDA-approved anti-leukemia drug with proven strong anti-tumor activity in solid tumors. In this study, we found that HHT could significantly inhibit HCC cell growth by suppressing cell proliferation and colony formation. Moreover, HHT repressed cell invasion and migration remarkably. Additionally, HHT induced cell cycle arrest at S phase and promoted apoptosis. Most importantly, we showed that HHT-induced apoptosis was a consequence of the Hippo pathway activation. Consistently, the MST1/2 inhibitor, XMU-MP-1, could restore cell viability and reverse HHT-induced cell apoptosis. Furthermore, in vivo results confirmed the tumor inhibitory effect of HHT. Taken together, our findings suggest that HHT is a potential alternative therapeutic agent for the treatment of HCC.

Sign in / Sign up

Export Citation Format

Share Document